Optimal reversal of vitamin K antagonists.
Schulman
Sam
S
D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000378:metabolism; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D005167:Factor VII / Q000627:therapeutic use; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D019934:International Normalized Ratio; D011516:Prothrombin / Q000737:chemistry; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced; D013997:Time Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D014812:Vitamin K; D005167:Factor VII; D011516:Prothrombin